Patient characteristics
| . | ALL (n = 174) . | FCM−/CC− (n = 156) . | FCM+/CC− (n = 11) . | FCM+/CC+ (n = 7) . |
|---|---|---|---|---|
| Male sex | 120 (69%) | 108 (69%) | 6 (54.5%) | 6 (86%) |
| Median age, y (IQR) | 56 (43-63) | 56.5 (43-64) | 47 (36.5-56.5) | 51 (44-63) |
| Histology | ||||
| Diffuse large B-cell (DLBCL) | 125 (72%) | 114 (73%) | 6 (54.5%) | 5 (71%) |
| Burkitt (BL) | 36 (21%) | 30 (19%) | 4 (36%) | 2 (29%) |
| Mantle cell (B-MCL) | 8 (5%) | 8 (5%) | 0 (0%) | 0 (0%) |
| B-LL | 5 (3%) | 4 (3%) | 1 (9%) | 0 (0%) |
| HIV infection | 36 (21%) | 32 (20.5%) | 2 (18%) | 2 (29%) |
| ECOG ≥ 2 | 64 (37%) | 54 (35%) | 5 (45.5%) | 5 (71%) |
| Presence of B symptoms | 79 (45%) | 69 (44%) | 5 (45.5%) | 5 (71%) |
| Ann Arbor ≥ 3 | 138 (79%) | 121 (78%) | 11 (100%) | 6 (86%) |
| Bulky disease | 48 (28%) | 40 (26%) | 5 (45.5%) | 3 (43%) |
| Median extranodal sites involved, no. (IQR)* | 1 (1-2) | 1 (1-2) | 2 (1-2.5) | 1 (1-2) |
| BM positive* | 52 (31%) | 42 (28%) | 5 (45.5%) | 5 (71%) |
| Testicular involvement* | 17 (10%) | 15 (10%) | 1 (9%) | 1 (14%) |
| Abnormal LDH | 113 (65%) | 98 (63%) | 10 (91%) | 5 (71%) |
| IPI | ||||
| 0-1 | 33 (19.5%) | 32 (21%) | 0 (0%) | 1 (14%) |
| 2 | 40 (24%) | 37 (24.5%) | 3 (27%) | 0 (0%) |
| 3 | 51 (30%) | 43 (28.5%) | 5 (45.5%) | 3 (43%) |
| 4-5 | 45 (27%) | 39 (26%) | 3 (27%) | 3 (43%) |
| Median (IQR) | 3 (2-4) | 3 (2-4) | 3 (2.5-3.5) | 3 (3-4) |
| Median proteins in CSF, mg/mL (IQR)* | 31 (22-43) | 30.5 (22-41) | 44 (25-47) | 51 (29-67) |
| Median cells in CSF, no. (IQR)* | 1 (0.0-2) | 0.015 (0.0-2) | 1 (0.0-1.7) | 12 (3.5-40) |
| . | ALL (n = 174) . | FCM−/CC− (n = 156) . | FCM+/CC− (n = 11) . | FCM+/CC+ (n = 7) . |
|---|---|---|---|---|
| Male sex | 120 (69%) | 108 (69%) | 6 (54.5%) | 6 (86%) |
| Median age, y (IQR) | 56 (43-63) | 56.5 (43-64) | 47 (36.5-56.5) | 51 (44-63) |
| Histology | ||||
| Diffuse large B-cell (DLBCL) | 125 (72%) | 114 (73%) | 6 (54.5%) | 5 (71%) |
| Burkitt (BL) | 36 (21%) | 30 (19%) | 4 (36%) | 2 (29%) |
| Mantle cell (B-MCL) | 8 (5%) | 8 (5%) | 0 (0%) | 0 (0%) |
| B-LL | 5 (3%) | 4 (3%) | 1 (9%) | 0 (0%) |
| HIV infection | 36 (21%) | 32 (20.5%) | 2 (18%) | 2 (29%) |
| ECOG ≥ 2 | 64 (37%) | 54 (35%) | 5 (45.5%) | 5 (71%) |
| Presence of B symptoms | 79 (45%) | 69 (44%) | 5 (45.5%) | 5 (71%) |
| Ann Arbor ≥ 3 | 138 (79%) | 121 (78%) | 11 (100%) | 6 (86%) |
| Bulky disease | 48 (28%) | 40 (26%) | 5 (45.5%) | 3 (43%) |
| Median extranodal sites involved, no. (IQR)* | 1 (1-2) | 1 (1-2) | 2 (1-2.5) | 1 (1-2) |
| BM positive* | 52 (31%) | 42 (28%) | 5 (45.5%) | 5 (71%) |
| Testicular involvement* | 17 (10%) | 15 (10%) | 1 (9%) | 1 (14%) |
| Abnormal LDH | 113 (65%) | 98 (63%) | 10 (91%) | 5 (71%) |
| IPI | ||||
| 0-1 | 33 (19.5%) | 32 (21%) | 0 (0%) | 1 (14%) |
| 2 | 40 (24%) | 37 (24.5%) | 3 (27%) | 0 (0%) |
| 3 | 51 (30%) | 43 (28.5%) | 5 (45.5%) | 3 (43%) |
| 4-5 | 45 (27%) | 39 (26%) | 3 (27%) | 3 (43%) |
| Median (IQR) | 3 (2-4) | 3 (2-4) | 3 (2.5-3.5) | 3 (3-4) |
| Median proteins in CSF, mg/mL (IQR)* | 31 (22-43) | 30.5 (22-41) | 44 (25-47) | 51 (29-67) |
| Median cells in CSF, no. (IQR)* | 1 (0.0-2) | 0.015 (0.0-2) | 1 (0.0-1.7) | 12 (3.5-40) |
Assessed on 169 patients (5 patients missing).